{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T08:54:37Z","timestamp":1780044877977,"version":"3.53.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinik M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Salvage radical prostatectomy (sRP) is an important treatment option for patients with recurrent prostate cancer (PCa) after radiotherapy (RT) or focal therapy (FT). However, health-related quality of life (HRQOL) after sRP depending on the primary treatment is understudied.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients who underwent Salvage RP for recurrent PCa were analyzed. The primary outcome of this study was HRQOL assessed by the quality-of-life questionnaire (QLQ)-C30 and its prostate specific QLQ-PR25 add-on. Secondary outcomes were functional outcome parameters (erectile function, continence) and biochemical recurrence-free survival (BRFS). Statistical analyses employed the chi-square test, Mann\u2013Whitney <jats:italic>U<\/jats:italic> test, and Kaplan\u2013Meier method, with a <jats:italic>p<\/jats:italic> value\u2009&lt;\u20090.05 denoting significance.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>37 patients with RT as primary treatment (RT-sRP) and 22 patients with focal therapy prior sRP (FT-sRP) were analyzed. Mean global health score was not significantly different preoperatively (71.9 vs. 67.3, <jats:italic>p<\/jats:italic>\u2009=\u20090.89) as well as after a median of 32\u00a0months follow-up (54.9 vs. 50.6, <jats:italic>p<\/jats:italic>\u2009=\u20090.63) with impaired HRQOL after sRP in both groups. Baseline erectile dysfunction was more prevalent in the RT-sRP group (mean IIEF-5: 5.0) than in the FT-sRP group (mean IIEF-5: 8.5, <jats:italic>p<\/jats:italic>\u2009=\u20090.037). No differences were observed at follow-up for erectile function (IIEF-5-Score: 0.5 vs 2.5, <jats:italic>p<\/jats:italic>\u2009=\u20090.199) and continence (continence rate: 48.4% vs 52.9% (<jats:italic>p<\/jats:italic>\u2009=\u20090.763) between the RT-sRP and FT-sRP group. 5-year-BRFS was 60% (RT-sRP) and 68% (FT-sRP, <jats:italic>p<\/jats:italic>\u2009=\u20090.849).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>sRP impacts HRQOL in patients with PCa after RT and FT with no significant differences. Comparison with HRQOL and BRFS of treatment alternatives is paramount to counsel patients for appropriate treatments.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00345-024-04945-y","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T14:01:48Z","timestamp":1713448908000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Health-related quality of life following salvage radical prostatectomy for recurrent prostate cancer after radiotherapy or focal therapy"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7600-6535","authenticated-orcid":false,"given":"Severin","family":"Rodler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Danninger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lennert","family":"Eismann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp Maximilian","family":"Kazmierczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich","family":"Jokisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minglun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kretschmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Stief","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thilo","family":"Westhofen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,18]]},"reference":[{"issue":"5","key":"4945_CR1","doi-asserted-by":"publisher","first-page":"296.e21","DOI":"10.1016\/j.urolonc.2020.11.002","volume":"39","author":"G Marra","year":"2021","unstructured":"Marra G et al (2021) Oncological outcomes of salvage radical prostatectomy for recurrent prostate cancer in the contemporary era: a multicenter retrospective study. Urol Oncol 39(5):296.e21-296.e29","journal-title":"Urol Oncol"},{"issue":"12","key":"4945_CR2","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.3390\/cancers15123123","volume":"15","author":"F Preisser","year":"2023","unstructured":"Preisser F et al (2023) Oncologic outcomes of lymph node dissection at salvage radical prostatectomy. Cancers (Basel) 15(12):3123","journal-title":"Cancers (Basel)"},{"issue":"8","key":"4945_CR3","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1007\/s00345-019-02749-z","volume":"37","author":"G Calleris","year":"2019","unstructured":"Calleris G et al (2019) Is it worth to perform salvage radical prostatectomy for radio-recurrent prostate cancer? A literature review. World J Urol 37(8):1469\u20131483","journal-title":"World J Urol"},{"issue":"5","key":"4945_CR4","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.eururo.2012.01.022","volume":"61","author":"DC Chade","year":"2012","unstructured":"Chade DC et al (2012) Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature. Eur Urol 61(5):961\u2013971","journal-title":"Eur Urol"},{"issue":"4","key":"4945_CR5","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/bju.14976","volume":"125","author":"JO Herrera-Caceres","year":"2020","unstructured":"Herrera-Caceres JO et al (2020) Salvage radical prostatectomy following focal therapy: functional and oncological outcomes. BJU Int 125(4):525\u2013530","journal-title":"BJU Int"},{"issue":"4","key":"4945_CR6","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1097\/JU.0000000000000327","volume":"202","author":"P Gontero","year":"2019","unstructured":"Gontero P et al (2019) Salvage radical prostatectomy for recurrent prostate cancer: morbidity and functional outcomes from a large multicenter series of open versus robotic approaches. J Urol 202(4):725\u2013731","journal-title":"J Urol"},{"issue":"1","key":"4945_CR7","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/bju.14900","volume":"125","author":"FF Onol","year":"2020","unstructured":"Onol FF et al (2020) Comparison of outcomes of salvage robot-assisted laparoscopic prostatectomy for post-primary radiation vs focal therapy. BJU Int 125(1):103\u2013111","journal-title":"BJU Int"},{"issue":"4","key":"4945_CR8","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.euf.2020.01.017","volume":"7","author":"A Kretschmer","year":"2021","unstructured":"Kretschmer A et al (2021) Health-related quality of life in patients with advanced prostate cancer: a systematic review. Eur Urol Focus 7(4):742\u2013751","journal-title":"Eur Urol Focus"},{"issue":"11","key":"4945_CR9","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1007\/s00345-015-1540-5","volume":"33","author":"A Kretschmer","year":"2015","unstructured":"Kretschmer A et al (2015) Surgical learning curve for open radical prostatectomy: is there an end to the learning curve? World J Urol 33(11):1721\u20131727","journal-title":"World J Urol"},{"issue":"5","key":"4945_CR10","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK et al (1993) The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365\u2013376","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"4945_CR11","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1007\/s11136-013-0387-8","volume":"22","author":"CF Snyder","year":"2013","unstructured":"Snyder CF et al (2013) Using the EORTC-QLQ-C30 in clinical practice for patient management: identifying scores requiring a clinician\u2019s attention. Qual Life Res 22(10):2685\u20132691","journal-title":"Qual Life Res"},{"issue":"4","key":"4945_CR12","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1002\/nau.20041","volume":"23","author":"K Avery","year":"2004","unstructured":"Avery K et al (2004) ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence. Neurourol Urodyn 23(4):322\u2013330","journal-title":"Neurourol Urodyn"},{"issue":"4","key":"4945_CR13","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/sj.ijir.3900859","volume":"14","author":"EL Rhoden","year":"2002","unstructured":"Rhoden EL et al (2002) The use of the simplified International Index of Erectile Function (IIEF-5) as a diagnostic tool to study the prevalence of erectile dysfunction. Int J Impot Res 14(4):245\u2013250","journal-title":"Int J Impot Res"},{"issue":"3","key":"4945_CR14","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1097\/JU.0000000000000295","volume":"202","author":"TM Pisansky","year":"2019","unstructured":"Pisansky TM et al (2019) Adjuvant and salvage radiotherapy after prostatectomy: ASTRO\/AUA guideline amendment 2018\u20132019. J Urol 202(3):533\u2013538","journal-title":"J Urol"},{"key":"4945_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-023-00728-5","author":"F Preisser","year":"2023","unstructured":"Preisser F et al (2023) Impact of persistent PSA after salvage radical prostatectomy: a multicenter study. Prostate Cancer Prostatic Dis. https:\/\/doi.org\/10.1038\/s41391-023-00728-5","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"4945_CR16","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/cncr.28446","volume":"120","author":"KC Cary","year":"2014","unstructured":"Cary KC et al (2014) Temporal trends and predictors of salvage cancer treatment after failure following radical prostatectomy or radiation therapy: an analysis from the CaPSURE registry. Cancer 120(4):507\u2013512","journal-title":"Cancer"},{"issue":"5","key":"4945_CR17","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","volume":"67","author":"PL Nguyen","year":"2015","unstructured":"Nguyen PL et al (2015) Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol 67(5):825\u2013836","journal-title":"Eur Urol"},{"issue":"1","key":"4945_CR18","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/j.1532-5415.2005.00567.x","volume":"54","author":"K Dacal","year":"2006","unstructured":"Dacal K, Sereika SM, Greenspan SL (2006) Quality of life in prostate cancer patients taking androgen deprivation therapy. J Am Geriatr Soc 54(1):85\u201390","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"4945_CR19","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.eururo.2019.08.017","volume":"77","author":"DJ Rosario","year":"2020","unstructured":"Rosario DJ, Bourke L (2020) Cardiovascular disease and the androgen receptor: here we go again? Eur Urol 77(2):167\u2013169","journal-title":"Eur Urol"},{"issue":"4","key":"4945_CR20","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.eururo.2018.06.018","volume":"74","author":"A Nabid","year":"2018","unstructured":"Nabid A et al (2018) Duration of androgen deprivation therapy in high-risk prostate cancer: a randomized phase III trial. Eur Urol 74(4):432\u2013441","journal-title":"Eur Urol"},{"issue":"9","key":"4945_CR21","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/S1470-2045(17)30426-6","volume":"18","author":"GM Duchesne","year":"2017","unstructured":"Duchesne GM et al (2017) Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol 18(9):1192\u20131201","journal-title":"Lancet Oncol"},{"key":"4945_CR22","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.urology.2021.04.059","volume":"156","author":"T Spitznagel","year":"2021","unstructured":"Spitznagel T et al (2021) Salvage robotic-assisted laparoscopic radical prostatectomy following focal high-intensity focused ultrasound for ISUP 2\/3 cancer. Urology 156:147\u2013153","journal-title":"Urology"},{"key":"4945_CR23","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.euros.2021.03.003","volume":"27","author":"A Nathan","year":"2021","unstructured":"Nathan A et al (2021) Salvage versus primary robot-assisted radical prostatectomy: a propensity-matched comparative effectiveness study from a high-volume tertiary centre. Eur Urol Open Sci 27:43\u201352","journal-title":"Eur Urol Open Sci"},{"key":"4945_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-023-00698-8","author":"R Nicoletti","year":"2023","unstructured":"Nicoletti R et al (2023) Functional outcomes and safety of focal therapy for prostate cancer: a systematic review on results and patient-reported outcome measures (PROMs). Prostate Cancer Prostatic Dis. https:\/\/doi.org\/10.1038\/s41391-023-00698-8","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"12","key":"4945_CR25","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1007\/s00345-020-03144-9","volume":"38","author":"A Kretschmer","year":"2020","unstructured":"Kretschmer A et al (2020) Health-related quality of life after open and robot-assisted radical prostatectomy in low- and intermediate-risk prostate cancer patients: a propensity score-matched analysis. World J Urol 38(12):3075\u20133083","journal-title":"World J Urol"},{"issue":"1","key":"4945_CR26","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.eururo.2021.08.005","volume":"81","author":"JS Hopstaken","year":"2022","unstructured":"Hopstaken JS et al (2022) An updated systematic review on focal therapy in localized prostate cancer: what has changed over the past 5 years? Eur Urol 81(1):5\u201333","journal-title":"Eur Urol"},{"issue":"10","key":"4945_CR27","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.3390\/cancers15102727","volume":"15","author":"F Blank","year":"2023","unstructured":"Blank F et al (2023) Salvage radical prostatectomy after primary focal ablative therapy: a systematic review and meta-analysis. Cancers 15(10):2727","journal-title":"Cancers"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-04945-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-024-04945-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-04945-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T21:27:09Z","timestamp":1735853229000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-024-04945-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,18]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4945"],"URL":"https:\/\/doi.org\/10.1007\/s00345-024-04945-y","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,18]]},"assertion":[{"value":"21 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S. R. receives consultancy fees from Merck, MSD and Novartis and owns shares of Rocketlane Medical Ventures GmbH. The other authors report no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"242"}}